Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis

Ryan, Caitriona; Menter, Alan; Guenther, Lyn; Blauvelt, Andrew; Bissonnette, Robert; Meeuwis, K.A.P.; Sullivan, John; Cather, Jennifer Clay; Yosipovitch, Gil; Gottlieb, Alice B.; Merola, Joseph F.; Duffin, Kristina Callis; Fretzin, Scott; Osuntokun, Olawale; Burge, Russel; Naegeli, April N.; Yang, Fan; Lin, Chen-Yen; Todd, K.; Bleakman, Alison Potts

doi:10.1111/bjd.16736

Cited by 94 publications

(63 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such clinical data may form an important foundation to support the evidence‐based care of psoriasis patients with itch symptoms. The following discussion reviews the itch effect of topical agents, systemics and biologics, and phototherapy, as revealed in recent studies (Table ) . Itch relief remains a significant gap in the treatment landscape for psoriasis, as not all patients are able to achieve control of this symptom, even with cleared or markedly improved skin.…”

Section: Management Of Itch In Psoriasismentioning

confidence: 99%

Itch: an under‐recognized problem in psoriasis

Elewski

Alexis

Lebwohl

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Psoriasis has historically been considered a nonpruritic dermatosis, in contrast with atopic dermatitis. Thus, itch has often been underappreciated and overlooked in psoriasis. However, increasing evidence over the past decade has shown that itch can be one of the most prevalent and burdensome symptoms associated with psoriasis, affecting almost every patient to some degree. Itch can involve the entire body, although it predominantly affects the legs, hands, back, body and especially the scalp. Uncontrolled itch can significantly impact all aspects of the well‐being and quality of life of the patient. While there has been some progress in trying to better understand the pathophysiology of itch in psoriasis, more research effort and interest are needed. This under‐recognition of itch in psoriasis is clearly reflected in the dearth of treatment options targeting itch despite significant advancement in treating the lesions themselves. Recently, however, clinical studies have begun to include itch as a study outcome. The resulting data have demonstrated concomitant antipruritic benefits and improved Psoriasis Area and Severity Index (PASI) scores with mainstay treatments for psoriasis, such as topical corticosteroids and vitamin D analogs, phototherapies, and various systemics and biologics. This article takes a closer look at this debilitating symptom, reviewing the available epidemiology data for psoriatic itch, presenting the current understanding of psoriatic itch pathophysiology and highlighting important clinical data for various treatment options for itch. Practical considerations for increasing the recognition of itch as well as improving its management in psoriasis are also provided.

show abstract

Section: Management Of Itch In Psoriasismentioning

confidence: 99%

Itch: an under‐recognized problem in psoriasis

Elewski

Alexis

Lebwohl

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, 6 out of 25 women with GenPs received Ixekizumab, 7 Ustekinumab, 8 Adalimumab, 2 Secukinumab, 1 Etanercept, 1 Certolizumab (Table ). Anti‐IL17 drug antibodies were administered to patients with a severe PASI (>15) or with latent tuberculosis, considering that this class of biologics has a low risk to activate tuberculosis (Ryan, ; Kaushik, 2018). Young patients with a moderate PASI (10–15), travelers, or patients with needle‐phobia, were given anti‐IL12/23, as injections have to be repeated just every 12 weeks (Yosipovitch, ; Kellen, ).…”

Section: Methodsmentioning

confidence: 99%

“…Recently, two double‐blinded, placebo‐controlled phase IIIb studies, demonstrated the superiority of Ixekizumab, an anti‐IL17, versus placebo, for the treatment of moderate‐to‐severe GenPs with BSA ≥1% improving also symptoms related to sexual activity (Ryan, ; Yosipovitch, ).…”

Section: Introductionmentioning

confidence: 99%

Biological therapy in genital psoriasis in women

Burlando

Herzum

Carmisciano

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…While, systemic treatment appeared to reduce the frequency of genital involvement, 24·5% of patients on conventional systemic treatment, and 23·3% of patients on biological treatments still had active genital psoriasis. Recently the first randomized controlled trial of a biological agent, ixekizumab, (an interleukin‐17 inhibitor), specifically in genital psoriasis revealed significant efficacy in the treatment of patients with moderate‐to‐severe genital disease . It is necessary that further controlled studies are conducted to adequately assess the efficacy of topical, systemic and biological treatments for genital psoriasis to optimize the management of those patients with difficult‐to‐treat genital disease.…”

mentioning

confidence: 99%